Amneal Pharmaceuticals Inc. Class A

5.67-0.0100-0.18%Vol 905.33K1Y Perf 71.06%
Apr 20th, 2021 16:00 DELAYED
BID5.50 ASK6.05
Open5.64 Previous Close5.68
Pre-Market- After-Market-
 - -  - -%
Target Price
5.79 
Analyst Rating
Hold 2.78
Potential %
2.12 
Finscreener Ranking
★★+     49.02
Insiders Trans % 3/6/12 mo.
-100/-100/33 
Value Ranking
★★★+     53.21
Insiders Value % 3/6/12 mo.
-100/-100/-27 
Growth Ranking
★★★+     57.44
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-4 
Income Ranking
 —    -
Market Cap1.70B 
Earnings Rating
Strong Buy
Price Range Ratio 52W %
59.36 
Earnings Date
7th May 2021

Today's Price Range

5.465.70

52W Range

3.077.45

Summary:

Sell

Technical Indicators: Sell
Moving Averages: Sell
Performance
1 Week
-2.58%
1 Month
-20.92%
3 Months
16.67%
6 Months
7.79%
1 Year
71.06%
3 Years
-71.51%
5 Years
-84.42%
10 Years
-78.57%

TickerPriceChg.Chg.%
AMRX5.67-0.0100-0.18
AAPL133.11-1.7300-1.28
GOOG2 293.63-8.7700-0.38
MSFT258.26-0.4800-0.19
XOM55.29-1.1900-2.11
WFC42.54-1.3400-3.05
JNJ166.483.79002.33
FB302.650.41000.14
GE13.06-0.4000-2.97
JPM149.27-3.3800-2.21
Earnings HistoryEstimateReportedSurprise %
Q04 20200.120.11-8.33
Q03 20200.120.138.33
Q02 20200.100.100.00
Q01 20200.070.18157.14
Q04 20190.030.07133.33
Q03 20190.120.00-100.00
Q02 20190.140.06-57.14
Q01 20190.180.11-38.89
Earnings Per EndEstimateRevision %Trend
3/2021 QR0.1741.67Positive
6/2021 QR0.176.25Positive
12/2021 FY0.7310.61Positive
12/2022 FY0.8114.08Positive
Next Report Date7th May 2021
Estimated EPS Next Report0.17
Estimates Count3
EPS Growth Next 5 Years %25.00
Volume Overview
Volume905.33K
Shares Outstanding299.82M
Trades Count5.66K
Dollar Volume7.73M
Avg. Volume1.94M
Avg. Weekly Volume752.84K
Avg. Monthly Volume1.31M
Avg. Quarterly Volume2.07M

Amneal Pharmaceuticals Inc. Class A (NYSE: AMRX) stock closed at 5.67 per share at the end of the most recent trading day (a -0.18% change compared to the prior day closing price) with a volume of 905.36K shares and market capitalization of 1.70B. Is a component of indices and it is traded on NYSE exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 5500 people. Amneal Pharmaceuticals Inc. Class A CEO is Chintu Patel / Chirag Patel.

The one-year performance of Amneal Pharmaceuticals Inc. Class A stock is 71.06%, while year-to-date (YTD) performance is 24.07%. AMRX stock has a five-year performance of -84.42%. Its 52-week range is between 3.07 and 7.45, which gives AMRX stock a 52-week price range ratio of 59.36%

Amneal Pharmaceuticals Inc. Class A currently has a PE ratio of 9.50, a price-to-book (PB) ratio of 2.88, a price-to-sale (PS) ratio of 0.56, a price to cashflow ratio of 2.30, a PEG ratio of 2.32, a ROA of 2.28%, a ROC of 5.49% and a ROE of 32.76%. The company’s profit margin is -4.59%, its EBITDA margin is 15.60%, and its revenue ttm is $1.49 Billion , which makes it $10.07 revenue per share.

Of the last four earnings reports from Amneal Pharmaceuticals Inc. Class A, there were 2 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $0.17 for the next earnings report. Amneal Pharmaceuticals Inc. Class A’s next earnings report date is 07th May 2021.

The consensus rating of Wall Street analysts for Amneal Pharmaceuticals Inc. Class A is Hold (2.78), with a target price of $5.79, which is +2.12% compared to the current price. The earnings rating for Amneal Pharmaceuticals Inc. Class A stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Amneal Pharmaceuticals Inc. Class A has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Amneal Pharmaceuticals Inc. Class A has a Sell technical analysis rating based on Technical Indicators (ADX : 15.62, ATR14 : 0.36, CCI20 : -107.11, Chaikin Money Flow : -0.12, MACD : 0.17, Money Flow Index : 30.51, ROC : -15.60, RSI : 55.69, STOCH (14,3) : 6.11, STOCH RSI : 0.00, UO : 40.90, Williams %R : -93.89), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Amneal Pharmaceuticals Inc. Class A in the last 12-months were: Anastasios G. Konidaris (Option Excercise at a value of $0), Andrew S. Boyer (Option Excercise at a value of $0), Chintu Patel (Option Excercise at a value of $0), Chirag Patel (Option Excercise at a value of $0), Emily Peterson Alva (Option Excercise at a value of $0), Gautam Patel (Option Excercise at a value of $0), J. Kevin Buchi (Option Excercise at a value of $0), Jeffrey P. George (Buy at a value of $198 099), Jeffrey P. George (Option Excercise at a value of $0), John J. Kiely (Buy at a value of $88 000), John J. Kiely (Option Excercise at a value of $0), Joseph Todisco (Option Excercise at a value of $99 908), Joseph Todisco (Sold 36 330 shares of value $247 865 ), Nikita Shah (Option Excercise at a value of $99 908), Nikita Shah (Sold 36 330 shares of value $249 489 ), Paul M. Meister (Option Excercise at a value of $0), Peter R. Terreri (Option Excercise at a value of $0), Shlomo Yanai (Option Excercise at a value of $0), Ted C. Nark (Option Excercise at a value of $0)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
2 (22.22 %)
2 (20.00 %)
2 (18.18 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
6 (66.67 %)
7 (70.00 %)
7 (63.64 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
1 (11.11 %)
1 (10.00 %)
2 (18.18 %)
Summary RatingHold
2.78
Hold
2.80
Hold
3.00

Amneal Pharmaceuticals Inc. Class A

Amneal Pharmaceuticals Inc is a generic pharmaceutical manufacturer. The company's reportable segments are Generic Products and Specialty products. Generics segment develops, manufactures and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals, and Specialty segment is engaged in the development, promotion, sale and distribution of proprietary branded pharmaceutical products. It generates a majority of its revenue from the Generic business segment.

CEO: Chintu Patel / Chirag Patel

Telephone: +1 908 947-3120

Address: 400 Crossing Boulevard, Bridgewater 08807, NJ, US

Number of employees: 5 500

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

100%0%

Bearish Bullish

70%30%

Bearish Bullish

62%38%

Bearish Bullish

67%33%

News

Stocktwits